AnaptysBio

📍 San Diego, United States🗓 Founded 2005👥 111 employees💰 Last funded Jan 2021
Biotechnology Research🌐 anaptysbio.com
Website LinkedIn
AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulating antibodies, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases: rosnilimab, our PD-1 agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; and ANB032, our BTLA agonist, in a planned Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases. AnaptysBio has developed two cytokine antagonists available for outlicensing: imsidolimab, an anti-IL-36r antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. AnaptysBio has also discovered antibodies licensed to GSK in a financial collaboration for immune-oncology, including an anti-PD-1 antagonist (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist (cobolimab, GSK4069889) and an anti-LAG-3 antagonist (GSK4074386).
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
2005
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in AnaptysBio?
AnaptysBio has 2 investors on record on gritt.io, including 1 early-stage backers.
When did AnaptysBio last raise funding?
The most recent investment in AnaptysBio recorded on gritt.io was in January 2021.
When was AnaptysBio founded?
AnaptysBio was founded in 2005.
What industry is AnaptysBio in?
AnaptysBio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AnaptysBio based?
AnaptysBio is headquartered in San Diego, United States.